SUNA 2019: Utilizing Change Management for Successful Implementation of Blue Light Cystoscopy

Lake Buena Vista, FL ( Poster detailed Rebecca Roe’s successful implementation of Hexaminolevulinate HCl (Cysview®) Blue Light Cystoscopy (BLC) in a community hospital outside of Atlanta. Hexaminolevulinate makes non-muscle invasive bladder cancer (NMIBC) tumors glow bright pink under blue light during a cystoscopy. It was approved by the US Food and Drug Administration (FDA) in June 2010.

Implementing BLC identified five management practices to ensure success: 1) ongoing communication, 2) clinical training, 3) use of mechanisms for measurement of feedback and redesign, 4) sustained attention; and 5) worker involvement. To gain the support of stakeholders, Roe introduced evidence supporting the benefits for using BLC compared to the standard white light cystoscopy. She then formed a multidisciplinary group invested in trialing the BLC. The nursing staff led the project and were instrumental in determining, through the trial outcomes, whether to adopt and invest in this technology. There were 17 patients in this BLC trial. Cysview® instillation time was 61 mins. Based on the trial, a workflow algorithm and checklist was developed for use. A logistical plan for sterile processing of BLC was put in place. A plan for medication mixing/labeling was developed with pharmacy. A competency for nurses and an electronic order set for providers were put in place.

Presented by: Rebecca Roe, MSN-Ed, CNOR, Clinical Education Program Coordinator Surgical Services Northside Hospital Forsyth, Gainesville, Georgia

Written by: Diane K. Newman, DNP, ANP-BC, FAAN, Adjunct Professor of Urology in Surgery, Perelman School of Medicine, University of Pennsylvania and Co-Director of the Penn Center for Continence and Pelvic Health at the Society of Urologic Nurses and Associates 50th Annual Meeting (SUNA 2019) September 20-23, 2019, Lake Buena Vista, FL